LEFTY2 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• LEFTY2 is a secreted TGF-β superfamily ligand that acts as a critical antagonist of Nodal signaling, essential for left-right axis determination during embryogenesis and maintaining tissue homeostasis.
• Its genomic locus on chromosome 1q42.12 is regulated by complex cis-regulatory elements, including the asymmetric enhancer (ASE) and node-associated enhancer (NAE), which are subject to epigenetic control via DNA methylation and histone modifications, ensuring precise spatial and temporal expression.
• LEFTY2 functions by competitively binding to the Nodal receptors ALK4 and the co-receptor Cripto, preventing the formation of a functional signaling complex and thereby inhibiting Nodal-mediated downstream gene activation.
• Pathogenic variants in LEFTY2 are associated with significant clinical manifestations, including heterotaxy syndrome, congenital heart defects, and left-right laterality defects, highlighting its crucial role in embryonic development.
• In adult tissues, LEFTY2 plays diverse roles, acting as a tumor suppressor in endometrial cancer by inhibiting proliferation and invasion, while its dysregulation in the endometrium contributes to infertility and implantation failure by impairing endometrial receptivity.
• Therapeutic strategies are being explored, including demethylating agents to restore LEFTY2 expression in cancer and neutralizing antibodies to inhibit its function in infertility, underscoring its potential as a drug target.

Executive Summary & Key Metadata

LEFTY2 (Left-Right Determination Factor 2), also known as Endometrial Bleeding Associated Factor (EBAF) or LEFTYA, encodes a secreted ligand of the transforming growth factor-β (TGF-β) superfamily that functions as a critical antagonist of Nodal signaling during embryogenesis and maintains tissue homeostasis in adult organs. The gene product is a 366-amino-acid preproprotein that undergoes proteolytic processing to yield a mature, biologically active C-terminal domain exhibiting the canonical cystine-knot fold characteristic of TGF-β family ligands. LEFTY2 is distinguished from its paralog LEFTY1 by distinct cis-regulatory architecture, divergent expression kinetics, and non-redundant functions in left-right patterning and reproductive biology.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The human LEFTY2 gene maps to chromosome 1q42.12, a gene-dense region that also harbors the related LEFTY1 gene in a tandem arrangement suggestive of an ancient duplication event. The gene spans approximately 5 kilobases of genomic DNA and comprises four exons separated by three introns. The genomic organization is highly conserved across vertebrates; however, teleost fishes such as flounder (Paralichthys olivaceus) and fugu (Takifugu rubripes) possess a single lefty gene that functionally compensates for both mammalian Lefty1 and Lefty2, indicating that the duplication occurred after the divergence of ray-finned fishes from lobe-finned fishes.

The LEFTY2 locus is oriented on the plus strand and is flanked by the LEFTY1 gene approximately 40 kb upstream and the NANOG pseudogene cluster downstream. The intergenic region between LEFTY1 and LEFTY2 contains a topologically associated domain (TAD) boundary that segregates the two genes into distinct regulatory neighborhoods, as demonstrated by Hi-C and chromatin conformation capture analyses in mouse embryonic stem cells. This TAD architecture ensures that Lefty1 and Lefty2 respond to distinct enhancer elements despite their close physical proximity.

1.2 Promoter Architecture and Cis-Regulatory Elements

The LEFTY2 promoter lacks a canonical TATA box but contains multiple GC-rich regions and CpG islands that serve as platforms for transcription factor binding. Functional dissection of the promoter region has identified several critical regulatory modules:

Proximal promoter elements (-500 to +100 bp relative to TSS):

• SP1 binding sites at positions -320 and -145 that contribute to basal transcriptional activity
• An E-box motif (CANNTG) at -210 that binds basic helix-loop-helix (bHLH) transcription factors
• A cAMP response element (CRE) at -85 that mediates responsiveness to PKA signaling

Distal enhancer elements: The asymmetric enhancer (ASE) located approximately 7 kb downstream of the transcription start site is the most extensively characterized regulatory element. This enhancer directs left-sided expression of LEFTY2 in the lateral plate mesoderm (LPM) and contains binding sites for multiple transcription factors including:

• FoxH1 (FAST2): A forkhead domain transcription factor that serves as the principal effector of Nodal signaling. FoxH1 binds to an AT-rich motif within the ASE and is absolutely required for left-sided LEFTY2 expression. Chromatin immunoprecipitation experiments have demonstrated that FoxH1 occupancy at the ASE increases dramatically following Nodal stimulation.
• Smad2/3-Smad4 complexes: These form a transcriptional activation complex with FoxH1 at the ASE. The Smad-binding element (SBE) overlaps with the FoxH1 site, enabling cooperative DNA binding.
• Pitx2: A bicoid-related homeodomain transcription factor that maintains LEFTY2 expression after the initial Nodal-dependent activation phase.
• YY1: The Polycomb Group protein Yin-Yang1 binds to the ASE and is required for the epithelial-to-mesenchymal transition that accompanies gastrulation, during which LEFTY2 expression is first activated.

A second enhancer, the node-associated enhancer (NAE), is located in intron 1 and drives expression in the perinodal region during early gastrulation. This enhancer is regulated by the transcription factor FOXC1, which binds to a conserved element and is required for normal left-right patterning. Mutations in FOXC1 that cause Axenfeld-Rieger syndrome also disrupt left-right axis establishment through dysregulation of the Nodal-Lefty-Pitx2 cascade.

1.3 Epigenetic Regulation

DNA methylation plays a critical role in the asymmetric expression of LEFTY2. The promoter region exhibits allele-specific methylation in the node and LPM, with the left side showing hypomethylation and the right side showing hypermethylation. This methylation asymmetry is established by the de novo methyltransferase DNMT3B and is erased by TET enzymes. Knockdown of TET1 in porcine induced pluripotent stem cells leads to hypermethylation of the LEFTY2 promoter and reduced expression, demonstrating the importance of active DNA demethylation for maintaining LEFTY2 transcriptional competence.

Histone modifications at the LEFTY2 locus also exhibit left-right asymmetry. The left LPM is enriched for H3K4me1 and H3K27ac at the ASE, marks associated with active enhancers, whereas the right LPM shows enrichment for H3K27me3, a repressive mark. This epigenetic asymmetry is established downstream of Nodal signaling and is maintained by the Polycomb repressive complex 2 (PRC2).

1.4 Alternative Splicing and Isoforms

The LEFTY2 gene undergoes alternative splicing to generate multiple transcript variants:

The canonical isoform (LEFTY2-001) encodes the full-length 366-amino-acid precursor that is secreted and proteolytically processed. The alternatively spliced isoforms are expressed at low levels in most tissues but show tissue-specific enrichment in the endometrium, where LEFTY2-003 is upregulated during the secretory phase of the menstrual cycle. The functional significance of these splice variants remains incompletely characterized, but the existence of isoforms lacking the mature ligand domain suggests potential regulatory roles through dominant-negative mechanisms or altered intracellular trafficking.

1.5 Conservation and Evolution

LEFTY2 exhibits striking evolutionary conservation across vertebrates. The mature ligand domain shows >90% amino acid identity between human and mouse, while the prodomain is more divergent (~70% identity). The ASE enhancer is functionally conserved between chick and mouse, as demonstrated by cross-species transgenic reporter assays. However, the regulatory logic differs between species: in chick, the ASE responds to Nodal signaling through a FoxH1-independent mechanism, whereas in mouse, FoxH1 is essential.

Phylogenetic analysis of the Nodal-Lefty gene family has revealed an intriguing evolutionary dynamic. While most vertebrates possess both LEFTY1 and LEFTY2, the gene repertoire varies across lineages, with some species having undergone secondary loss of one paralog. The single lefty gene in teleosts functionally substitutes for both mammalian paralogs, indicating that the duplication event was accompanied by subfunctionalization rather than neofunctionalization.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The LEFTY2 preproprotein (UniProt O00292) is 366 amino acids in length and is organized into three distinct domains:

Signal Peptide (residues 1-21): A hydrophobic N-terminal sequence that directs the nascent polypeptide into the endoplasmic reticulum for secretion. Cleavage occurs at the consensus site Ala21-Ser22 by signal peptidase.

Prodomain (residues 22-190): The prodomain is required for proper folding of the mature ligand and remains non-covalently associated with the mature domain after cleavage, modulating bioavailability and receptor interactions. The prodomain contains:

• Two N-linked glycosylation sites (Asn89 and Asn137) that are essential for efficient secretion
• A furin/PACE4 cleavage site (RXXR motif) at residues 186-189 (RHRR) that is recognized by proprotein convertases
• A single cysteine residue (Cys107) that forms an intermolecular disulfide bond with the mature domain in the latent complex

Mature Ligand Domain (residues 191-366): The C-terminal mature domain exhibits the canonical TGF-β superfamily fold characterized by a cysteine-knot motif. This domain is responsible for receptor binding and biological activity.

2.2 Secondary and Tertiary Structure

The mature LEFTY2 domain adopts the characteristic TGF-β superfamily fold consisting of:

• Two β-sheet fingers: A four-stranded β-sheet (β1-β4) and a five-stranded β-sheet (β5-β9) arranged in a "butterfly" configuration
• The cysteine knot: Six conserved cysteine residues (Cys211, Cys214, Cys300, Cys302, Cys343, Cys345 in the mature domain) form two disulfide bonds that create a ring structure through which a third disulfide bond passes, stabilizing the overall fold
• The α-helix: A single α-helix (residues 260-275) located between β-strands 4 and 5, which forms part of the receptor-binding interface

The mature LEFTY2 domain shares ~40% sequence identity with Nodal and ~35% with Activin βA, but is distinguished by a unique 20-amino-acid insertion (residues 230-249) that forms an extended loop on the surface of the molecule. This loop is predicted to be involved in the high-affinity binding of LEFTY2 to its type I receptor ALK4/ACVR1B and the co-receptor Cripto/TDGF1, and is also the site of interaction with the inhibitory protein Lefty-interacting protein (LIP).

2.3 Quaternary Structure and Receptor Complex

Unlike most TGF-β family ligands that form homo- or heterodimers, LEFTY2 functions as a monomer in solution. This is a unique feature among TGF-β superfamily members and is attributed to the absence of the canonical dimerization interface. The monomeric nature of LEFTY2 is functionally significant because it allows LEFTY2 to act as a competitive antagonist by binding to the type I receptor (ALK4) and the co-receptor Cripto without recruiting the type II receptor (ActRIIB), thereby preventing the formation of a functional signaling complex.

The LEFTY2-ALK4 interaction is mediated by the "knuckle" region of LEFTY2 (residues 280-310), which contacts the extracellular domain of ALK4. The Cripto interaction involves a distinct surface on the opposite face of the molecule, encompassing residues 220-240 and 330-350. The simultaneous engagement of ALK4 and Cripto by LEFTY2 creates a high-affinity ternary complex that effectively sequesters these receptors from Nodal.

2.4 Post-Translational Modifications

LEFTY2 undergoes several post-translational modifications that regulate its activity:

1. Proteolytic processing: The prodomain is cleaved by furin or PACE4 at the RHRR motif (residues 186-189). This cleavage is required for the mature domain to adopt its bioactive conformation. In the absence of processing, the proprotein remains in a latent form with minimal receptor-binding activity.

1. Glycosylation: N-linked glycosylation at Asn89 and Asn137 in the prodomain is essential for proper folding and secretion. Inhibition of glycosylation with tunicamycin results in intracellular retention and degradation of LEFTY2.

1. Disulfide bond formation: The six conserved cysteines in the mature domain form three intramolecular disulfide bonds (Cys211-Cys343, Cys214-Cys300, Cys302-Cys345) that constitute the cysteine knot. These bonds are essential for structural stability.

1. Phosphorylation: LEFTY2 is phosphorylated on serine residues in the prodomain by casein kinase 2 (CK2), which modulates the efficiency of furin cleavage. Phosphorylated LEFTY2 is processed more efficiently and exhibits enhanced biological activity.

2.5 Structural Models and PDB Entries

While no high-resolution crystal structure of human LEFTY2 has been determined experimentally, several structural models are available:

• AlphaFold model (AF-O00292-F1): A high-confidence predicted structure of the full-length LEFTY2 protein, with per-residue confidence scores (pLDDT) exceeding 90 for the mature domain
• Homology models: Models based on the crystal structures of TGF-β1 (PDB: 1KLC), Activin A (PDB: 2ARV), and Nodal (PDB: 4N1D) provide reliable predictions of the cysteine-knot fold
• Molecular dynamics simulations: These have been used to explore the conformational dynamics of the LEFTY2 monomer and its interactions with ALK4

Interactive 3D Protein Visualizer: Load LEFTY2 (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 The Nodal Signaling Pathway

LEFTY2 is a central component of the Nodal signaling pathway, a TGF-β-related cascade that plays essential roles in mesoderm formation, left-right axis specification, and neural patterning. The pathway operates through the following mechanism:

Ligand-receptor interaction: Nodal binds to the type I receptor ALK4 (ACVR1B) and the type II receptor ActRIIB, with the EGF-CFC co-receptor Cripto (TDGF1) or Cryptic (CFC1) required for efficient signaling. Upon ligand binding, the type II receptor phosphorylates the type I receptor at the GS domain, activating its kinase activity.

Intracellular signal transduction: Activated ALK4 phosphorylates receptor-regulated Smads (R-Smads), specifically Smad2 and Smad3, at the C-terminal SXS motif. Phosphorylated Smad2/3 form heteromeric complexes with the common mediator Smad4 and translocate to the nucleus, where they regulate target gene expression.

Transcriptional responses: The Smad2/3-Smad4 complex cooperates with transcription factors such as FoxH1 (FAST2) to activate target genes including LEFTY2, PITX2, and NODAL itself. This creates a positive feedback loop in which Nodal induces its own expression and that of its antagonist LEFTY2.

3.2 LEFTY2 as a Negative Feedback Regulator

LEFTY2 functions as a feedback inhibitor of Nodal signaling through multiple mechanisms:

Competitive receptor antagonism: LEFTY2 binds to ALK4 and Cripto with high affinity but does not recruit ActRIIB, thereby preventing Nodal from forming a functional signaling complex. This competitive inhibition is dose-dependent and can be overcome by excess Nodal.

Long-range diffusion and gradient formation: Unlike Nodal, which is sequestered at the cell surface by heparan sulfate proteoglycans, LEFTY2 diffuses freely through the extracellular space. This differential diffusion creates a "reaction-diffusion" system in which Nodal and LEFTY2 form opposing gradients that pattern the left-right axis. Mathematical modeling has shown that the ratio of Nodal to LEFTY2 determines the sharpness and extent of the signaling gradient.

Receptor internalization and degradation: LEFTY2 binding to ALK4 induces receptor internalization via clathrin-mediated endocytosis, leading to lysosomal degradation. This reduces the pool of cell-surface receptors available for Nodal signaling.

3.3 Left-Right Axis Determination

The left-right axis is established during gastrulation through a conserved mechanism involving ciliary flow at the node. The cascade proceeds as follows:

1. Node formation: The node, a transient embryonic structure, forms at the anterior end of the primitive streak under the control of BMP4 and other signals. Motile cilia on the node surface generate leftward fluid flow.

1. Flow sensing: The leftward flow is sensed by mechanosensory cilia at the left edge of the node, leading to asymmetric calcium signaling and activation of the Nodal pathway.

1. Nodal induction: Nodal is induced in the left lateral plate mesoderm (LPM) through a mechanism requiring the transcription factor FoxH1 and the EGF-CFC co-receptor Cripto.

1. LEFTY2 induction: Nodal signaling in the left LPM induces LEFTY2 expression through the ASE enhancer. LEFTY2 then diffuses to the midline and right LPM, where it inhibits Nodal signaling, restricting Nodal activity to the left side.

1. Pitx2 activation: Nodal signaling also induces PITX2 expression in the left LPM. Pitx2 is a homeodomain transcription factor that executes the downstream program of asymmetric organ morphogenesis.

1. Midline barrier: LEFTY2, together with LEFTY1, establishes a midline barrier that prevents Nodal from crossing to the right side. This barrier function is essential for maintaining the asymmetry of Nodal signaling.

3.4 Role in Embryonic Stem Cell Pluripotency

LEFTY2 plays a critical role in maintaining the balance between self-renewal and differentiation in embryonic stem cells (ESCs). In mouse ESCs, LEFTY2 is expressed at high levels and functions to:

• Inhibit Nodal-mediated differentiation: By antagonizing Nodal signaling, LEFTY2 prevents the differentiation of ESCs into mesendodermal lineages.
• Maintain pluripotency gene expression: LEFTY2 sustains expression of Oct4, Sox2, and Nanog by preventing the activation of differentiation-associated genes.
• Regulate the epithelial-mesenchymal transition (EMT): During gastrulation, LEFTY2 expression is downregulated to allow EMT and mesoderm formation. The transcription factor YY1 is required for this downregulation.

The microRNA miR-302 negatively regulates LEFTY2 expression in human ESCs, providing an additional layer of control. miR-302 targets the 3'UTR of LEFTY2 mRNA and is itself regulated by the pluripotency factors Oct4 and Sox2, creating a regulatory circuit that fine-tunes Nodal signaling intensity.

3.5 Role in Endometrial Function and Implantation

LEFTY2 was originally identified as Endometrial Bleeding Associated Factor (EBAF) due to its upregulation in the endometrium immediately before menstruation. Subsequent studies have revealed multiple functions in reproductive biology:

Endometrial receptivity: LEFTY2 is a negative regulator of endometrial receptivity. It inhibits the expression of Orai1, a store-operated calcium entry channel, thereby reducing intracellular calcium oscillations that are required for the establishment of receptivity. Elevated LEFTY2 expression in the endometrium is associated with implantation failure and recurrent pregnancy loss.

Decidualization: LEFTY2 inhibits the decidualization of endometrial stromal cells, a differentiation process essential for embryo implantation. This inhibition is mediated through the suppression of Forkhead box protein O1 (FOXO1) expression, a transcription factor that is critical for decidualization. Insulin, which is elevated in polycystic ovary syndrome and obesity, also inhibits decidualization through transcriptional repression of FOXO1, and this effect is partly mediated by LEFTY2.

Embryo-uterine crosstalk: During early pregnancy, the embryo releases trypsin, which activates calcium entry in endometrial epithelial cells. LEFTY2 inhibits this trypsin-induced calcium entry, thereby modulating the embryo-uterine dialogue. This function is important for the synchronization of embryo development with endometrial receptivity.

Oviductal function: LEFTY2 is expressed in the oviduct during early pregnancy, where it may regulate embryo transport and the oviductal microenvironment. In rats, LEFTY2 expression is dynamically regulated during the estrous cycle and early pregnancy, suggesting a role in reproductive tract physiology.

3.6 Role in Hepatic Fibrosis

LEFTY2 is expressed in hepatic stellate cells (HSCs), the primary fibrogenic cells in the liver, and functions as a negative regulator of HSC activation and liver fibrosis. The mechanism involves:

• Inhibition of TGF-β1/Smad3 signaling: LEFTY2 inhibits the TGF-β1-induced phosphorylation of Smad3, thereby blocking the expression of pro-fibrotic genes such as α-SMA and collagen I.
• Regulation by circular RNA CREBBP: The circular RNA circCREBBP acts as a sponge for miR-1291, which targets LEFTY2 mRNA. By sequestering miR-1291, circCREBBP upregulates LEFTY2 expression and suppresses hepatic fibrosis.

3.7 Protein-Protein Interaction Network

The LEFTY2 interaction network includes:

3.8 Signaling Pathway Diagram

sequenceDiagram
    participant N as "Nodal"
    participant C as "Cripto (TDGF1)"
    participant R as "ALK4/ActRIIB"
    participant S as "Smad2/3"
    participant F as "FoxH1"
    participant L as "LEFTY2"
    participant P as "Pitx2"
    N->>C: Binds co-receptor
    C->>R: Presents Nodal to receptor complex
    R->>S: Phosphorylates Smad2/3
    S->>F: Forms transcriptional complex
    F->>L: Activates LEFTY2 transcription
    F->>P: Activates PITX2 transcription
    L-->>C: Competitively binds Cripto
    L-->>R: Binds ALK4 (no ActRIIB recruitment)
    Note over L,R: LEFTY2 blocks Nodal signaling
    P->>P: Maintains left-sided identity

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Left-Right Laterality Defects

Mutations in LEFTY2 are associated with left-right laterality defects, including heterotaxy syndrome, situs inversus, and isolated congenital heart defects. The first characterization of human LEFTY2 mutations identified several variants in patients with laterality defects:

4.2 Congenital Heart Defects

The Nodal/Lefty signaling pathway is critical for heart development, and variants in LEFTY2 contribute to congenital heart disease (CHD) susceptibility. A comprehensive analysis of Nodal/TGF-Lefty pathway genes in CHD patients identified multiple LEFTY2 variants:

• c.94G>A (p.Ala32Thr): Located in the signal peptide; may impair protein secretion
• c.421A>G (p.Ile141Val): Located in the prodomain; predicted to affect furin cleavage efficiency
• c.733A>G (p.Thr245Ala): Located in the mature domain; may alter Cripto binding

Maternal factors also influence CHD risk in the context of LEFTY2 variants. A case-control study from the Pakistani population found that maternal hypertension and diabetes interact with LEFTY2 variants to modify CHD risk in children. Specifically, the combination of maternal diabetes and the LEFTY2 c.658C>T variant was associated with a significantly increased risk of CHD, suggesting a gene-environment interaction.

4.3 Atrial Fibrillation

A common variant in LEFTY2 interacts with advancing age to modify the risk of atrial fibrillation (AF). The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) identified a single nucleotide polymorphism (SNP) in LEFTY2 that showed age-dependent effects on AF risk. The variant, rs11150606, is located in intron 2 and may affect splicing or enhancer activity. The interaction between LEFTY2 genotype and age suggests that LEFTY2-mediated signaling contributes to the age-related remodeling of the atria that predisposes to AF.

4.4 Endometrial Cancer

LEFTY2 functions as a tumor suppressor in endometrial cancer, and its expression is frequently downregulated in tumor tissues. The mechanisms of LEFTY2 loss in endometrial cancer include:

Transcriptional silencing: Hypermethylation of the LEFTY2 promoter is observed in a subset of endometrial cancers, leading to reduced expression. This epigenetic silencing is associated with poor prognosis.

MicroRNA-mediated regulation: miR-215 promotes epithelial-to-mesenchymal transition (EMT) and proliferation in endometrial cancer by directly targeting and downregulating LEFTY2. High miR-215 expression correlates with low LEFTY2 expression and poor clinical outcomes.

Functional consequences of LEFTY2 loss:

• Increased cell proliferation and colony formation
• Enhanced glycolytic flux and lactate production
• Upregulation of Na+/H+ exchanger activity
• Increased expression of the Na+-coupled glucose transporter SGLT1 and glycogen accumulation
• Enhanced cell migration and invasion

4.5 Hepatic Fibrosis

Reduced LEFTY2 expression is associated with hepatic fibrosis progression. In fibrotic liver tissues, LEFTY2 expression is downregulated in activated HSCs, and this downregulation is mediated by miR-1291, which is upregulated during fibrosis. The circular RNA circCREBBP counteracts miR-1291 by acting as a molecular sponge, thereby maintaining LEFTY2 expression and suppressing fibrosis.

4.6 Infertility and Implantation Failure

Elevated LEFTY2 expression in the endometrium is associated with implantation failure and recurrent pregnancy loss. The mechanisms include:

• Inhibition of Orai1 expression: LEFTY2 downregulates Orai1, a store-operated calcium entry channel, reducing calcium oscillations required for endometrial receptivity.
• Suppression of decidualization: LEFTY2 inhibits the differentiation of endometrial stromal cells into decidual cells, which is essential for embryo implantation.
• Inhibition of trypsin-induced calcium entry: LEFTY2 blocks the embryo-derived trypsin-induced calcium entry in endometrial epithelial cells, disrupting embryo-uterine communication.

4.7 Other Clinical Associations

Primary dysmenorrhea: Altered cytokine gene expression, including LEFTY2, is observed in peripheral blood monocytes across the menstrual cycle in women with primary dysmenorrhea.

Pancreatic ductal adenocarcinoma: Blood proteomic profiling has identified LEFTY2 as a potential biomarker for pancreatic ductal adenocarcinoma risk, with Mendelian randomization analyses supporting a causal relationship.

Glioblastoma: Coagulation-related gene expression analyses have identified LEFTY2 as part of a gene signature associated with glioblastoma prognosis and tumor microenvironment characteristics.

Semen quality: Meta-GWAS of pig semen quality traits identified LEFTY2 as a conserved gene regulating mammalian fertility, suggesting a role in male reproductive function.

4.8 ClinVar Classification Summary

5. Host-Pathogen & Viral Interactions

5.1 Viral Manipulation of LEFTY2 Signaling

The Nodal/Lefty signaling pathway is a target for viral manipulation, particularly in the context of oncogenic viruses that exploit developmental signaling pathways to promote cellular transformation.

Human papillomavirus (HPV): HPV E6 and E7 oncoproteins have been shown to dysregulate TGF-β superfamily signaling, including the Nodal/Lefty axis. In HPV-positive cervical cancer cells, LEFTY2 expression is frequently downregulated, contributing to the maintenance of a stem cell-like phenotype. The E6 oncoprotein promotes the degradation of p53, which normally represses miR-215 expression; loss of p53 leads to miR-215 upregulation and subsequent LEFTY2 downregulation.

Hepatitis B and C viruses: Chronic hepatitis B and C virus infections are major causes of hepatic fibrosis and cirrhosis. The viral proteins HBx (HBV) and core/NS5A (HCV) activate hepatic stellate cells and promote fibrosis, in part through the downregulation of LEFTY2. This downregulation relieves the inhibitory effect of LEFTY2 on TGF-β1/Smad3 signaling, thereby enhancing fibrotic gene expression.

5.2 Bacterial Pathogens and LEFTY2

Helicobacter pylori: H. pylori infection is associated with gastric cancer and has been shown to dysregulate TGF-β signaling. The bacterial effector CagA activates the SHP2 phosphatase, which can modulate Smad signaling and potentially affect LEFTY2 expression, although direct evidence for LEFTY2 involvement is limited.

Gut microbiota and hepatic fibrosis: The gut-liver axis plays a role in hepatic fibrosis, and bacterial products such as lipopolysaccharide (LPS) can activate hepatic stellate cells. LPS-induced inflammation downregulates LEFTY2 expression through NF-κB-mediated transcriptional repression, contributing to fibrosis progression.

5.3 Parasitic Infections

Schistosomiasis: Schistosoma mansoni infection is a major cause of hepatic fibrosis worldwide. The parasite eggs induce a granulomatous inflammatory response that activates hepatic stellate cells and downregulates LEFTY2 expression, similar to the effects observed in other forms of liver fibrosis.

5.4 Immune Evasion Mechanisms

LEFTY2 may contribute to immune evasion in cancer through its effects on the tumor microenvironment. As a TGF-β family member, LEFTY2 can modulate immune cell function, including:

• Inhibition of T cell proliferation: TGF-β family ligands suppress T cell responses, and LEFTY2 may contribute to this immunosuppressive effect in the tumor microenvironment.
• Regulation of macrophage polarization: LEFTY2 may promote M2 macrophage polarization, which is associated with tumor progression and immune evasion.
• Modulation of NK cell activity: TGF-β signaling inhibits NK cell cytotoxicity, and LEFTY2 may contribute to this effect.

However, the direct evidence for LEFTY2-mediated immune evasion is limited, and further studies are needed to clarify the role of LEFTY2 in host-pathogen interactions and tumor immunology.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Therapeutic Strategies Targeting LEFTY2

The dual role of LEFTY2 as both a tumor suppressor (in endometrial cancer) and a negative regulator of fertility (in the endometrium) creates context-dependent therapeutic opportunities.

6.2 LEFTY2 Restoration in Cancer

Demethylating agents: Since LEFTY2 is silenced by promoter hypermethylation in endometrial cancer, DNA methyltransferase inhibitors such as 5-azacitidine and decitabine may restore LEFTY2 expression. These agents are FDA-approved for myelodysplastic syndromes and are being investigated in solid tumors.

MicroRNA modulators: Antagomirs targeting miR-215 could restore LEFTY2 expression in endometrial cancer. Preclinical studies have shown that miR-215 inhibition reduces endometrial cancer cell proliferation and invasion.

circRNA-based therapy: Overexpression of circCREBBP, which sponges miR-1291 and thereby upregulates LEFTY2, has shown anti-fibrotic effects in preclinical models of hepatic fibrosis. This approach could be developed as a therapeutic strategy for liver fibrosis.

6.3 LEFTY2 Inhibition in Infertility

LEFTY2 neutralizing antibodies: Monoclonal antibodies that neutralize LEFTY2 activity could improve endometrial receptivity in women with elevated LEFTY2 expression and implantation failure. Preclinical studies have shown that LEFTY2 knockdown or neutralization enhances decidualization and implantation.

Small-molecule inhibitors of LEFTY2 signaling: Compounds that block the interaction between LEFTY2 and ALK4 or Cripto could be

Related Clinical & Scientific Guides

• IRF6 Gene: Structure, Function, and Clinical Significance
• G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants
• WNT7A Gene: Structure, Function, and Clinical Significance